Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Semax vs Other Neuroprotective Peptides in Stroke Research

Semax (ACTH 4-10 analog) BDNF upregulation, melanocortin receptor agonism Phase III (Russia), Phase I (USA) 9mg intranasal daily × 10 days or 600mcg SC BID × 14 days ≤72 hours optimal, benefit up to 7 days Strongest human evidence for functional recovery. Dosi

This comparison does not assign a generated winner or score.

  • Semax (ACTH 4-10 analog)
  • BDNF upregulation, melanocortin receptor agonism
  • Phase III (Russia), Phase I (USA)
  • 9mg intranasal daily × 10 days or 600mcg SC BID × 14 days
  • ≤72 hours optimal, benefit up to 7 days
  • Strongest human evidence for functional recovery. Dosing flexibility between intranasal and subcutaneous routes allows protocol adaptation
  • Cerebrolysin (porcine brain-derived peptides)
  • Multifactorial neurotrophic support
  • Phase III (multiple countries)
  • 30–50mL IV daily × 10–21 days
  • ≤24 hours
  • Comparable efficacy to semax in meta-analyses but requires IV administration. Logistically complex for acute settings
  • Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)
  • Hepatocyte growth factor (HGF) mimetic, synaptic remodelling
  • Preclinical only (no human stroke trials)
  • Not established. Animal models used 1–5mg/kg
  • Unknown in humans
  • Potent neuroplasticity effects in animal models, but zero clinical stroke data. Speculative until Phase I trials occur
  • P21 (NAPVSIPQ fragment)
  • CNTF receptor activation, dendritic complexity
  • Preclinical
  • Not established
  • Unknown
  • Interesting cognitive enhancement profile in rodent stroke models but no published human trials
  • Thymalin (thymus extract peptides)
  • Immune modulation, indirect neuroprotection
  • Phase II
  • 10mg IM daily × 10 days
  • Post-acute phase (>7 days)
  • Weak direct neuroprotective evidence. May reduce post-stroke infections and secondary complications but not a primary neuroregenerative agent
  • The critical distinction is between neuroprotection (preventing further damage) and neurorestoration (rebuilding function). Semax demonstrates both properties, whereas most stroke peptides under investigation target only the first. The BDNF mechanism specifically drives axonal sprouting and synaptogenesis in surviving tissue. This is why functional gains appear weeks after administration ends, not just during the acute dosing period.